ImageneBio (IMA) Non-Current Debt (2023 - 2024)
ImageneBio's (IMA) quarterly Non-Current Debt came in at $1.1 million in Q4 2024, up 11.68% year-over-year from $950000.0 in Q1 2024, and up 11.68% quarter-over-quarter from $950000.0 in Q4 2023.
Powered by 
Analysis
ImageneBio (IMA) Non-Current Debt (2023 - 2024) Analysis & Trends
ImageneBio has disclosed Non-Current Debt across 2 years of filings, most recently posting $1.1 million for Q4 2024.
- In Q4 2024, Non-Current Debt rose 11.68% year-over-year to $1.1 million; the TTM figure through Dec 2024 stood at $1.1 million (up 11.68% YoY), while the FY2024 annual figure was $1.1 million, up 11.68% from the prior year.
- Non-Current Debt came in at $1.1 million for Q4 2024 at ImageneBio, up from $950000.0 in the prior quarter.
- In the past five years, Non-Current Debt ranged from a high of $1.1 million in Q4 2024 to a low of $852000.0 in Q3 2023.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Debt (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 206.44 Bn | 192.45 Bn | 7.24 Bn | 57.30 Bn |
| 2 | Gilead Sciences | 179.97 Bn | 176.79 Bn | 6.22 Bn | 26.25 Bn |
| 3 | Vertex Pharmaceuticals | 130.57 Bn | 122.72 Bn | 2.84 Bn | - |
| 4 | Regeneron Pharmaceuticals | 81.63 Bn | 73.63 Bn | 3.93 Bn | 1.99 Bn |
| 5 | Argenx Se | 60.34 Bn | 55.16 Bn | 1.37 Bn | - |
| 6 | Moderna | 54.37 Bn | 49.23 Bn | 52.00 Mn | 591.00 Mn |
| 7 | Alnylam Pharmaceuticals | 33.07 Bn | 29.76 Bn | 992.69 Mn | - |
| 8 | Biogen | 31.84 Bn | 30.55 Bn | 1.96 Bn | 7.29 Bn |
| 9 | Roivant Sciences | 29.49 Bn | 29.49 Bn | 1.16 Mn | - |
| 10 | ImageneBio | 42.89 Mn | -92.46 Mn | - | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Dec 31, 2024 | 1.06 Mn |
| Dec 31, 2023 | 950,000.00 |
| Sep 30, 2023 | 852,000.00 |